Your browser doesn't support javascript.
loading
HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia.
Martínez Buitrago, Ernesto; Oñate, José Millán; García-Goez, José Fernando; Álvarez, Jorge; Lenis, William; Sañudo, Luz Marina; Rubiano, Luisa Consuelo.
Afiliación
  • Martínez Buitrago E; Fundación Red de VIH del Valle del Cauca (REVIVA), Cali, Colombia. emarbui@gmail.com.
  • Oñate JM; Universidad del Valle, Cali, Colombia. emarbui@gmail.com.
  • García-Goez JF; Fundación Red de VIH del Valle del Cauca (REVIVA), Cali, Colombia.
  • Álvarez J; Centro Médico Imbanaco, Cali, Colombia.
  • Lenis W; Fundación Red de VIH del Valle del Cauca (REVIVA), Cali, Colombia.
  • Sañudo LM; Hospital Universitario Fundación Valle del Lili, Cali, Colombia.
  • Rubiano LC; Universidad Icesi, Cali, Colombia.
BMC Infect Dis ; 19(1): 793, 2019 Sep 09.
Article en En | MEDLINE | ID: mdl-31500584
BACKGROUND: The HLA-B*57:01 allele is associated with a hypersensitivity reaction to abacavir. Due to the lack of knowledge of HLA-B*57:01 prevalence in Colombia, routine screening is not performed and is not recommended by the national guidelines. We aimed to determine the prevalence of HLA-B*57:01 in HIV population from Colombia. METHODS: This cross-sectional study included naïve HIV-infected adults from 13 cities of the country. The presence of HLA-B*57:01 was determined by using SSP-PCR in blood samples. Prevalence rates were stratified by sex, race, and region of origin. RESULTS: HLA-B*57:01 allele prevalence in Colombian HIV-infected individuals was 2.7%. When stratifying for the race, the prevalence was 4% for whites, 2.6% for other race (mainly mestizo), and 1.9% for Afro-Colombians. The prevalence varied from 0% up to 11.4% depending on the department of origin. The highest prevalence rates were found in Caldas (11.4%), Antioquia (5%), Risaralda (4.8%), and Valle del Cauca (4.3%). When distributed by country zones, the central, with a racial predominance of Caucasians and mestizos, was the highest (6.0%, 0R = 4.1, CI 1.2-12.8, p = 0,016). CONCLUSIONS: The overall prevalence of HLA-B*57:01 in Colombia was lower than the reported rates for other Latin American countries such as Brazil, Costa Rica, and Argentina, but similar in comparison to Chile and Mexico. The diversity in the racial and ethnic heritage shown in our data supports the recommendation to implement routine screening for the HLA-B*57:01 allele before initiation of abacavir-containing antiretroviral therapy in the Colombian HIV management guidelines.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antígenos HLA-B / Infecciones por VIH / Hipersensibilidad a las Drogas Tipo de estudio: Guideline / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: America do sul / Colombia Idioma: En Revista: BMC Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2019 Tipo del documento: Article País de afiliación: Colombia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antígenos HLA-B / Infecciones por VIH / Hipersensibilidad a las Drogas Tipo de estudio: Guideline / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: America do sul / Colombia Idioma: En Revista: BMC Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2019 Tipo del documento: Article País de afiliación: Colombia Pais de publicación: Reino Unido